https://www.avient.com/sites/default/files/resources/PolyOne%2520Investor%2520Presentation%2520Longbow%2520Basic%2520Materials%2520Conference%2520-%2520March%25202016.pdf
PolyOne Corporation Page 1
PolyOne Investor Presentation
March 2016
PolyOne Corporation Page 2
Forward-Looking Statements
In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995.
You are advised to
consult any further disclosures we make on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the Securities and Exchange
Commission.
1) Special items are a non-GAAP financial measure and are used to determine adjusted earnings.
https://www.avient.com/news/avient-develops-new-hardness-grades-high-performance-barricade-elastomers-portfolio
The softest durometer in this product line, the new 50A grade, offers exceptional haptics for enhanced user comfort.
https://www.avient.com/sites/default/files/resources/POL%2520IR%2520Presentation%2520Wells%2520Fargo%252005%252008%25202014%2520w%2520non%2520GAAP.pdf
PolyOne Corporation Investor Day 2012
PolyOne Investor Presentation
5th Annual Wells Fargo
Industrial and Construction Conference
May 8, 2014
• In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995.
You are advised to
consult any further disclosures we make on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the Securities and Exchange Commission.
Adjusted EPS 2006Y* 2007Y* 2008Y* 2009Y* 2010Y 2011Y 2012Y 2013Y
Net Income attributable to PolyOne common
shareholders $ 130.9 $ 40.9 $ (417.0) $ 106.7 $ 152.5 $ 153.4 $ 53.3 $ 94.0
SunBelt equity earnings, after tax (68.5) (26.1) (20.8) (19.0)
(14.7) (3.7) - -
Special items, after tax (21.2) 41.4 310.0 (31.0) 15.8 (30.5) 35.7 30.4
Tax adjustments (30.0) (30.7) 147.2 (44.9) (88.3) (42.3) 0.5 2.2
Adjusted net income $ 11.2 $ 25.5 $ 19.4 $ 11.8 $ 65.3 $ 76.9 $ 89.5 $ 126.6
Diluted shares 92.8 93.1 92.7 93.4 96.0 94.3 89.8 96.5
Adjusted EPS $ 0.12 $ 0.27 $ 0.21 $ 0.13 $ 0.68 $ 0.82 $ 1.00 $ 1.31
* Historical results are shown as presented in prior filings and have not been updated to reflect subsequent changes in accounting
principal or discontinued operations.
https://www.avient.com/sites/default/files/2021-03/avient-march-ir-fermium_0.pdf
Microsoft PowerPoint - Avient March IR - Fermium
AVIENT CORPORATION
(NYSE: AVNT)
M A R C H 1 8 , 2 0 2 1
I R M E E T I N G S
H O S T E D B Y
F E R M I U M R E S E A R C H
DISCLAIMER
2
Forward-Looking Statements
In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
You are advised to consult any further disclosures we make on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the Securities and Exchange Commission.
We are Avient.
4
BETTER TOGETHER: POLYONE AND
CLARIANT MASTERBATCH
Key Financial Data (1)
2021E Sales $4.1 billion
2021E EBITDA $510 million
2021E Free Cash Flow $250 million
87% of EBITDA from specialty applications
(1) As of February 9, 2021 webcast
Innovation is the lifeblood of a specialty company.
https://www.avient.com/sites/default/files/resources/PDI_Case_Study_-_Medical_Device_0.pdf
PDICaseStudy.indd
8.5 in
11.6875 in
8 .75 in
11.9375 in
8 .25 in
11 in
PDI Solution Boosts Long-Term
Medical Device Performance
Spinal disc replacement manufacturer relies on quality
analysis and manufacturing solutions from Polymer
Diagnostics to help its breakthrough product reach far
beyond durability requirements.
Asset No. 76593C M Y K PDICaseStudy.indd REMAY 76593
trim: 8.5in x 11in and 8.25in x 11.6875in bleed: 8.75in x 11.9375in Digital/IAM
8.5 in
11.6875 in
8 .75 in
11.9375 in
8 .25 in
11 in
www.polymerdiagnost ics.com
Copyright © 2008, Polymer Diagnostics Inc.
CONTACT INFORMATION
Polymer Diagnostics Inc.
33587 Walker Road
Avon Lake, Ohio 44012
United States
+1 800 438 2335
+1 440 930 1644 fax
Polymer Diagnostics Inc. is a contract laboratory with accreditation to ISO/IEC 17025 by the
American Association for Laboratory Accreditation (A2LA) for both chemical and mechanical
capacities.
https://www.avient.com/sites/default/files/2022-09/Avient Pro Forma Financial Information.pdf
Pro Forma Financial Information
The Company acquired Avient Protective Materials (“Dyneema”) on September 1, 2022 (the “Acquisition Date”) and has a pending sale of the Distribution segment.
To provide comparable results, the company references “pro forma” financial metrics,
which include the business results of Avient Protective Materials for periods prior to the Acquisition Date, as if the transaction occurred on January 1, 2021 and reflect Distribution as a discontinued operation.
Additionally, Adjusted EPS excludes the impact of special
items and amortization expense associated with intangible assets.
2
PRO FORMA 2021 TO 2022 BRIDGE
3
2021 EPS from Continuing Operations 1.69$
Pro Forma & Special Items 1.33
Proforma 2021 Adjusted EPS 3.02$
FX Impact (0.22)
China Lockdowns / Russia Import Sales (0.24)
Outdoor High Performance (0.13)
Dyneema 0.06
Color, Additives and Inks 0.38
Legacy Specialty Engineered Materials 0.22
Other 0.01
Proforma 2022 Adjusted EPS 3.10$
COLOR, ADDITIVES AND INKS
7% (4%) (9%)
6% (10%)
0% 1%
2%
7%
10% 4% (3%)
12% (6%)
5% 6%
9%
610 650 624 649 587 565 581 526
2,402 2,390
589 650 589 649 543 565 545 526
2,266 2,390
116 121 112 119 93 95 88 79
409 414
113 121 106 119 87 95 84 79
390 414
10%
4
(1%)
PRO FORMA SPECIALTY ENGINEERED MATERIALS
16%8% (8%) (8%) 3% (6%) (6%)
(2%) 2%
20%12% (1%) (2%) 5% (1%) (2%)
3% 6%
314 338 348 343 325 300 321 295
1,308 1,276
303 338 329 343 303 300 301 295
1,236 1,276
67 78 75 77 70 66 66 62
278 283
65 78 73 77 67 66 63 62
268 283
5
Constant Currency Adjusted EPS
Adjusted EPS
PRO FORMA AVIENT
10% (3%) (21%)
3%
9% 5%
7% (5%) (9%)
(1%)
(1%) (12%)
1%
17% 8% (14%)
11%
14% 10%
11% 2% (3%)
5%
8% (5%)
7%
925 987 973 992 912 867 902 823
3,712 3,669
893 987 919 992 847 867 845 823
3,504 3,669
161 176 164 172 142 141 133 117
600 606
155 176 157 172 131 141 123 117
566 6068%
2%
0.84 0.98 0.87 0.96 0.70 0.68 0.61 0.48
3.02 3.10
0.79 0.98 0.82 0.96 0.63 0.68 0.56 0.48
2.80 3.10
17%
24%
6
March 31, 2022
March 31, 2021
Net income from continuing operations $ 64.7 $ 60.4
Net income attributable to noncontrolling interests (0.3) (0.4)
Net income from continuing operations attributable to Avient shareholders $ 64.4 $ 0.70 $ 60.0 $ 0.65
Special items, after tax $ 6.4 $ 0.07 $ 2.6 $ 0.03
APM pro forma adjustments 2.6 0.03 (3.1) (0.03)
Amortization expense, after tax 17.4 0.19 17.9 0.19
Adjusted pro forma net income / EPS $ 90.8 $ 0.98 $ 77.4 $ 0.84
Weighted average diluted shares 92.3 92.2
June 30, 2022
June 30, 2021
Net income from continuing operations $ 62.8 $ 50.2
Net income attributable to noncontrolling interests — (0.6)
Net income from continuing operations attributable to Avient shareholders $ 62.8 $ 0.68 $ 49.6 $ 0.54
Special items, after tax $ 3.2 $ 0.03 $ 11.7 $ 0.13
APM pro forma adjustments 5.2 0.06 1.4 0.02
Amortization expense, after tax 17.2 0.19 17.8 0.19
Adjusted pro forma net income / EPS $ 88.4 $ 0.96 $ 80.5 $ 0.87
Weighted average diluted shares 92.1 92.4
September 30, 2021
Reconciliation to Condensed Consolidated Statements of Income Avient EPS
Net income from continuing operations $ 33.4
Net income attributable to noncontrolling interests 0.3
Net income from continuing operations attributable to Avient shareholders $ 33.7 $ 0.37
Special items, after tax $ 11.7 $ 0.13
APM pro forma adjustments 1.5 0.02
Amortization expense, after tax 17.6 0.19
Adjusted pro forma net income / EPS $ 64.5 $ 0.70
Weighted average diluted shares 92.2
Adjusted EPS may not recalculate due to rounding.
1
December 31, 2021
Year Ended
December 31, 2021
Net income from continuing operations $ 11.2 $ 155.2
Net income attributable to noncontrolling interests 0.9 0.2
Net income from continuing operations attributable to Avient shareholders $ 12.1 $ 0.13 $ 155.4 $ 1.69
Special items, after tax $ 24.0 $ 0.26 $ 50.0 $ 0.54
APM pro forma adjustments 2.5 0.03 1.6 0.02
Amortization expense, after tax 17.8 0.19 71.1 0.77
Adjusted pro forma net income / EPS $ 56.4 $ 0.61 $ 278.1 $ 3.02
Weighted average diluted shares 92.4 92.1
Reconciliation of Color, Additives and Inks EBITDA
Operating
Income 88.8 86.3 66.8 61.2 303.1 94.5 93.6
Depreciation and
amortization 27.4 25.3 26.6 26.4 105.7 26.0 25.9
EBITDA $ 116.2 $ 111.6 $ 93.4 $ 87.6 $ 408.8 $ 120.5 $ 119.5
Q1 2021 Q2 2021 Q3 2021
Pro
forma
Pro
forma
Pro
forma
Pro
forma
Pro
forma
Pro
forma
Operating Income 32.6 9.1 41.7 35.8 13.9 49.7 30.0 15.2 45.2
Depreciation and
amortization 7.8 17.5 25.3 8.1 17.3 25.4 7.9 17.1 25.0
EBITDA $ 40.4 $ 26.6 $ 67.0 $ 43.9 $ 31.2 $ 75.1 $ 37.9 $ 32.3 $ 70.2
Q4 2021 YTD 2021
Pro
forma
Pro
forma
Pro
forma
Pro
forma
Operating Income 27.1 11.7 38.8 125.5 49.9 175.4
Depreciation and amortization 8.0 18.9 26.9 31.8 70.8 102.6
EBITDA $ 35.1 $ 30.6 $ 65.7 $ 157.3 $ 120.7 $ 278.0
2
Q1 2022 Q2 2022
Pro
forma
Pro
forma
Pro
forma
Pro
forma
Operating Income 38.3 15.4 53.7 35.2 17.7 52.9
Depreciation and amortization 7.8 16.6 24.4 7.7 16.6 24.3
EBITDA $ 46.1 $ 32.0 $ 78.1 $ 42.9 $ 34.3 $ 77.2
Q1 2021 Q2 2021 Q3 2021
Pro
forma
Pro
forma
Pro
forma
Pro
forma
Pro
forma
Pro
forma
Net income from
continuing operations 60.4 (3.1) 57.3 50.2 1.4 51.6 33.4 1.5 34.9
Income tax expense 16.3 1.1 17.4 13.8 1.3 15.1 2.0 2.5 4.5
Interest expense 19.3 11.1 30.4 19.5 11.2 30.7 19.0 11.2 30.2
Depreciation and
amortization 36.9 17.5 54.4 33.6 17.3 50.9 36.6 17.1 53.7
EBITDA 132.9 26.6 159.5 117.1 31.2 148.3 91.0 32.3 123.3
Special items, before
tax 2.4 — 2.4 14.2 — 14.2 19.9 — 19.9
Depreciation included
in special items (0.6) — (0.6) 1.4 — 1.4 (0.9) — (0.9)
Adjusted EBITDA $ 134.7 $ 26.6 $ 161.3 $ 132.7 $ 31.2 $ 163.9 $ 110.0 $ 32.3 $ 142.3
Q4 2021 YTD 2021
Pro
forma
Pro
forma
Pro
forma
Pro
forma
Net income from continuing operations 11.2 2.5 13.7 155.2 1.6 156.8
Income tax expense 16.2 (1.9) 14.3 48.3 3.7 52.0
Interest expense 17.5 11.1 28.6 75.3 44.6 119.9
Depreciation and amortization 37.9 18.9 56.8 145.0 70.8 215.8
EBITDA 82.8 30.6 113.4 423.8 120.7 544.5
Special items, before tax 20.6 — 20.6 57.1 — 57.1
Depreciation included in special items (1.6) — (1.6) (1.7) — (1.7)
Adjusted EBITDA $ 101.8 $ 30.6 $ 132.4 $ 479.2 $ 120.7 $ 599.9
3
Q1 2022 Q2 2022
Pro
forma
Pro
forma
Pro
forma
Pro
forma
Net income from continuing operations 64.7 2.6 67.3 62.8 5.2 68.0
Income tax expense 20.0 1.7 21.7 22.7 1.4 24.1
Interest expense 16.9 11.1 28.0 16.2 11.1 27.3
Depreciation and amortization 37.6 16.6 54.2 36.3 16.6 52.9
EBITDA 139.2 32.0 171.2 138.0 34.3 172.3
Special items, before tax 6.6 — 6.6 0.9 — 0.9
Depreciation included in special items (2.1) — (2.1) (1.1) — (1.1)
Adjusted EBITDA $ 143.7 $ 32.0 $ 175.7 $ 137.8 $ 34.3 $ 172.1
Reconciliation of Specialty Engineered Pro Forma Sales
Sales 214.7 238.9 231.7 226.3 911.6 243.1 242.3
Pro forma APM 98.9 108.8 93.8 94.9 396.4 94.8 100.5
Pro forma sales $ 313.6 $ 347.7 $ 325.5 $ 321.2 $ 1,308.0 $ 337.9 $ 342.8
Reconciliation of Avient Pro Forma Sales
Sales 826.0 864.5 818.0 807.1 3,315.6 892.2 891.0
Pro forma APM 98.9 108.8 93.8 94.9 396.4 94.8 100.5
Pro forma sales $ 924.9 $ 973.3 $ 911.8 $ 902.0 $ 3,712.0 $ 987.0 $ 991.5
4
IR Slides
V17 - 9.26 324pm IR Deck - AVNT-2022.09.27 Pre Release v2
https://www.avient.com/sites/default/files/resources/Gabelli%2520Conf%2520-%2520POL%2520IR%2520Presentation%2520wNon%2520GAAP%2520Reconciliation%252003%252026%252015.pdf
PolyOne Corporation Page 1
PolyOne Investor Presentation
Gabelli Specialty Chemicals Conference
March 2015
PolyOne Corporation Page 2
Forward-Looking Statements
In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995.
You are
advised to consult any further disclosures we make on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the Securities and
Exchange Commission.
Adjusted EPS 2006Y* 2007Y* 2008Y* 2009Y* 2010Y 2011Y 2012Y 2013Y 2014Y
Net income attributable to
PolyOne common
shareholders $ 130.9 $ 40.9 $ (417.0) $ 106.7 $ 152.5 $ 153.4 $ 53.3 $ 94.0 $ 78.0
Joint venture equity
earnings, after tax (68.5) (26.1) (20.8) (19.0) (14.7) (3.7) - - -
Special items, after tax (21.2) 41.4 310.0 (31.0) 15.8 (30.5) 35.7 30.4 101.0
Tax adjustments (30.0) (30.7) 147.2 (44.9) (88.3) (42.3) 0.5 2.2 (10.5)
Adjusted net income $ 11.2 $ 25.5 $ 19.4 $ 11.8 $ 65.3 $ 76.9 $ 89.5 $ 126.6 $ 168.5
Diluted shares 92.8 93.1 92.7 93.4 96.0 94.3 89.8 96.5 93.5
Adjusted EPS $ 0.12 $ 0.27 $ 0.21 $ 0.13 $ 0.68 $ 0.82 $ 1.00 $ 1.31 $ 1.80
* Historical results are shown as presented in prior filings and have not been updated to reflect subsequent changes in accounting principal or discontinued operations.
https://www.avient.com/sites/default/files/2020-11/gls-tpes-soft-touch-selection-guide.pdf
GENERAL PURPOSE GLS TPES FOR PACKAGING
SOFT TOUCH GRIPS BONDING TO POLAR SUBSTRATES
GENERAL PURPOSE GLS TPES FOR PACKAGING
SOFT TOUCH GRIPS BONDING TO NON POLAR SUBSTRATES
Dynaflex™
G2711
Dynaflex™
G2780
Dynaflex™
G6713
Dynaflex™
G7960
Versalloy™
XL9045
Versaflex™
CL40
Aesthetics Grippy, 43A
Low tack, 84A
Extra soft, 13A
Rubbery, 60A
& opaque
Matte, 45A
& natural
Grippy, 40A
& water clear
Special
Characteristics
Grippy medical
grade PP & PE OM Extra soft General
purpose
High flow &
fast setup Water clear
Regulatory FDA, EU &
USP VI FDA FDA & EU FDA FDA FDA & EU
Overmolding Polypropylene Polypropylene &
Polyethylene Polypropylene Polypropylene Polypropylene Polypropylene
Versaflex™
CL 2250
Versaflex™
OM 3060
Versaflex™
CE 3120-65
Versaflex™
CE 3620
Versollan™
RU 2205
Aesthetics Grippy, 50A
& clear
Grippy, 59A
& clear
Silky feel, 65A
Silky feel, 65A
Grippy, 65A
Special
Characteristics Clear overmold Clear overmold Abrasion resistance
& high strength
Low compression set
& high flow
Abrasion resistance
& high strength
Regulatory FDA & USP VI FDA & USP VI UL 94 FDA &
ISO 10993-10 —
Overmolding Polycarbonate Polycarbonate
& ABS
Polycarbonate,
ABS, Copolyester
& Nylon 12
Polycarbonate,
ABS, Copolyester
& Nylon 12
1.844.4AVIENT
www.avient.com
Copyright © 2020, Avient Corporation.
https://www.avient.com/resources/safety-data-sheets?page=3881
NEUSoft 50A Grey 8C
X S1054A F-1
PP FR 8-6 LMS-1000
https://www.avient.com/resources/safety-data-sheets?page=3210
Geon(TM) PX-C-232C 50A Moldable
PC81 BEIGE PP 25:1
PP FR 8-6 LMS-1000